Survodutide, a novel dual glucagon receptor and GLP-1 receptor agonist, induces dose-dependent and sustained weight loss in adults with obesity and type 2 diabetes (T2D).
Robust improvements in glycemic control and biomarkers of beta-cell function and insulin sensitivity have been demonstrated, largely independent of weight loss magnitude.
Phase 3 SYNCHRONIZE-2 trial results establish significant superiority of once-weekly survodutide (3.6 mg and 6.0 mg) over placebo for weight reduction and HbA1c decrease over 76 weeks.
Gastrointestinal adverse events are the most common side effects, generally mild to moderate and transient, consistent with GLP-1 receptor agonist class effects.
